Comparison of Hydralazine and Labetalol to lower severe hypertension in pregnancy

Dr. Samuel J. Panara; Dr. Parul T. Shah; Dr. Kruti J. Deliwala

Volume : VI, Issue : XII, December - 2017

Comparison of Hydralazine and Labetalol to lower severe hypertension in pregnancy

Dr. Samuel J. Panara, Dr. Parul T. Shah, Dr. Kruti J. Deliwala

Abstract :

Objective: To compare the intravenous Labetalol versus intravenous hydralazine in patients having severe Pregnancy induced hypertension (PIH) and pre eclampsia (PE) in pregnancy.

Methods: Seventy eight women admitted in the Department of Gynecology and Obstetrics, V.S.General Hospital Ahmedabad, having severe PIH/PE and fulfilling the inclusion criteria were included in the study. Random selection of patients was performed using sealed opaqe envelop for administration of either intravenous noted (IV) Labetalol or Hydrallazine. The mean fall in the MAP in each group was noted. The study was conducted from November 2016 to April 2017.

Results: The mean (�SD) age of the labetalol group was 27.46 (�5.28) years while that in the hydralazine group was 26.28 (�5.17) years. The mean fall in MAP observed in the labetalol group was 29.10 � 7.21mmHg and that in the hydralazine group was 25.05 � 10.15 mmHg which was statistically significant with the p value being 0.046.

Conclusion: Intra Venous labetalol lowered MAP more than hydralazine, when administered to pregnant females with severe Pregnancy induced hypertension and pre eclampsia in pregnancy.